Target, Home Depot,...
Health Care: Drugs
Sarepta Therapeutics Inc (SRPT: NASDAQ)
$36.91 1.40 | 3.94%
05/17/13 - 04:00 PM ET
Portfolios with SRPT
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- UserWatch
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- User2012 picks 10/28/20121
- UserKJP Save Stockpickr Fund
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks With Big Insider Buy...
Latest SRPT Headlines from TheStreet
- Stocks Rebound Mirrors Markets After Madrid, London Bombings 04.16.13 | 04:04 pm
- Sarepta Stock Gaps Down On Today's Open (SRPT) 04.16.13 | 09:04 am
- A Proactive FDA Is Already Reviewing Sarepta's Muscular Dystrophy Drug 04.15.13 | 05:04 pm
- Sarepta Fans: A Single Data Slide Raises Questions About Glaxo's DMD Drug 04.12.13 | 10:04 am
- Cramer's 6 Stocks in 60 Seconds: IBM MWE SRPT ABC AGU QCOM (Update 1) 04.10.13 | 05:04 pm
- Hey Sarepta Investors: Glaxo's Drisapersen Data Revealed Early 04.09.13 | 02:04 pm
- Sarepta-Glaxo Duchenne's Rivalry Heats Up This Week 04.08.13 | 10:04 am
- 5 Stocks Rising on Unusual Volume 04.05.13 | 02:04 pm
- Sarepta's Eteplirsen Boys Keep On Walking 04.05.13 | 09:04 am
- Cramer's Top Stock Picks: WM VRTX SRPT NPSP DR 04.03.13 | 06:04 am
Press Releases for SRPT
- Over $400 Million Raised By U.S. Life Sciences Companies Through At-the-Market (ATM) Offerings In 2012, Reports Brinson Patrick - PR Newswire 04.08.13 | 08:04 am
- Over 25 Companies To Present At Emerald Groundhog Day Investment Forum - Business Wire 02.05.13 | 10:02 am
Partner Headlines for SRPT
- Thursday's BioPharma Trade Movers - Seeking Alpha 04.18.13 | 09:04 am
- Muscular Dystrophy Drug Succeeds, Sarepta Buyers Flood In - Seeking Alpha 04.11.13 | 09:04 am
- Barron's Recap (3/23/13): World's Best CEOs - Benzinga 03.24.13 | 01:03 pm
- Sarepta Therapeutics Setting Up For Another Move Upward - Seeking Alpha 01.31.13 | 09:01 am
- Raptor To Rise On Proven Strategy & Upcoming FDA Decision - Seeking Alpha 12.28.12 | 09:12 am
- UPDATE: Burril Initiates Sarepta Therapeutics at Market Outperform on Eteplirsen Potential - Benzinga 11.26.12 | 09:11 am
- Sarepta Therapeutics to Present Additional 48-Week Data From the Phase IIb Study of Eteplirsen for Treatment of Duchenne Muscular Dystrophy - Benzinga 10.12.12 | 04:10 pm
- 5 Bio-Pharmas On The Rise With Potential Groundbreaking And Lifesaving Treatments - Seeking Alpha 10.09.12 | 09:10 am
- Benzinga Mid-Morning Market Update - Benzinga 10.05.12 | 01:10 pm
- 3 Interesting Moves In Biotech Stocks From Wednesday - Seeking Alpha 10.04.12 | 09:10 am
